No increased cardiovascular mortality among early rheumatoid arthritis patients: A nationwide register study in 2000-2008

Clinical and Experimental Rheumatology

Volumn 33, Issue 3, 2015, Pages 391-398

  Kerola, Anne M ^a   Nieminen, Tuomo V M ^b,c   Virta, Lauri J ^d   Kautiainen, Hannu ^b,e   Kerola, Tuomas ^f   Pohjolainen, Timo ^g   Kauppi, Markku J ^f,h   Puolakka, Kari ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^g Kuntoutus ORTON   (Finland)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Cardiovascular diseases; Mortality; Rheumatoid arthritis

Indexed keywords

GLUCOCORTICOID; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; AGE; AGE DISTRIBUTION; AGED; ANIMAL; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; CAT; EPIDEMIOLOGY; INCIDENCE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; TIME FACTOR; VERY ELDERLY;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CARDIOVASCULAR DISEASES; CATS; CAUSE OF DEATH; FEMALE; FINLAND; GLUCOCORTICOIDS; HUMANS; INCIDENCE; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; REGISTRIES; RHEUMATOID FACTOR; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; TIME FACTORS;

EID: 84939559493     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. AVINA-ZUBIETA JA, CHOI HK, SADATSAFAVI M et al.: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
2. KEROLA AM, KAUPPI MJ, KEROLA T et al.: How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Ann Rheum Dis 2012; 71: 1606-15.
3. KEROLA AM, KEROLA T, KAUPPI MJ et al.: Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1826-9.
4. MYASOEDOVA E, DAVIS JM 3rd, CROWSON CS et al.: Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010; 12: 379-85.
5. PUOLAKKA K, KAUTIAINEN H, POHJOLAINEN T et al.: No increased mortality in incident cases of rheumatoid arthritis during the new millennium. Ann Rheum Dis 2010; 69: 2057-8.
6. RADOVITS BJ, FRANSEN J, Al SHAMMA S et al.: Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 2010; 62: 362-70.
7. RANTALAIHO V, KORPELA M, LAASONEN L et al.: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122.
8. LASSERE MN, RAPPO J, PORTEK IJ et al.: How many life years are lost in patients with rheumatoid arthritis?. Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern Med J 2013; 43: 66-72.
9. HUMPHREYS JH, WARNER A, CHIPPING J et al.: Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2014; 66: 1296-301.
10. MARKS JL, EDWARDS CJ: with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012; 4: 149-57.
11. DAVIS JM 3rd, MARADIT-KREMERS H, GABRIEL SE: Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect?. J Rheumatol 2005; 32: 1856-62.
12. WESTLAKE SL, COLEBATCH AN, BAIRD J et al.: Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011; 50: 518-31.
13. WESTLAKE SL, COLEBATCH AN, BAIRD J et al.: The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307.
14. Del RINCON I, BATTAFARANO DF, RESTREPO JF et al.: Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 264-72.
15. LISTING J, KEKOW J, MANGER B et al.: Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 2015; 74: 415-21.
16. SIHVONEN S, KORPELA M, MUSTONEN J et al.: Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 2006; 33: 1740-6.
17. LAHTI RA, PENTTILA A: The validity of death certificates: routine validation of death certification and its effects on mortality statistics. Forensic Sci Int 2001; 115: 15-32.
18. PAJUNEN P, KOUKKUNEN H, KETONEN M et al.: The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 132-7.
19. FURU K, WETTERMARK B, ANDERSEN M et al.: The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
20. ATC/DDD Index 2013. WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no/atc_ddd_index/. Accessed: 18 Dec 2013.
21. MEUNE C, TOUZE E, TRINQUART L et al.: Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009; 48: 1309-13.
22. SATTAR N, MCCAREY DW, CAPELL H et al.: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
23. YOUNG A, KODURI G, BATLEY M et al.: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46: 350-7.
24. KHAN EA, STAMP LK, O'DONNELL JL et al.: Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999-2008. Int J Rheum Dis 2013; 16: 19-23.
25. HOLMQVIST ME, WEDREN S, JACOBSSON LT et al.: Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268: 578-85.
26. NAZ SM, FARRAGHER TM, BUNN DK et al.: The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008; 58: 985-9.
27. SOLOMON DH, AVORN J, KATZ JN et al.: Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 3790-8.
28. SOUVEREIN PC, BERARD A, Van STAA TP et al.: Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-65.
29. ATZENI F, TURIEL M, CAPORALI R et al.: The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010; 9: 835-9.
30. PIERINGER H, PICHLER M: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 2011; 104: 13-26.
31. van SIJL AM, BOERS M, VOSKUYL AE et al.: Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One 2014; 9: e87965.
32. RANTALAIHO V, KAUTIAINEN H, VIRTA L et al.: Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. Scand J Rheumatol 2011; 40: 16-21.
33. MICHA R, IMAMURA F, WYLER von BALLMOOS M et al.: Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70.
34. CHOI HK, HERNAN MA, SEEGER JD et al.: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
35. WASKO MC, DASGUPTA A, HUBERT H et al.: Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65: 334-42.
36. GREENBERG JD, KREMER JM, CURTIS JR et al.: Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576-82.
37. REISS AB, CARSONS SE, ANWAR K et al.: Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58: 3675-83.
38. RIDKER PM: Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7 (Suppl. 1): 332-9.
39. BERGSTROM U, GRUNDTMAN C, LUNDBERG IE et al.: Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis. Clin Exp Rheumatol 2014; 32: 883-90.
40. TAM LS, GLADMAN DD, HALLETT DC et al.: Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142-5.
41. CAIROLI E, REBELLA M, DANESE N et al.: Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012; 21: 1178-82.
42. AKKARA VEETIL BM, MYASOEDOVA E, MATTESON EL et al.: Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol 2013; 40: 1082-8.
43. LINDHARDSEN J, AHLEHOFF O, GISLASON GH et al.: Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2012; 71: 1496-501.
44. AJEGANOVA S, ANDERSSON ML, FROSTEGARD J et al.: Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 2013; 40: 1958-66.
45. TOMASSON G, ASPELUND T, JONSSON T et al.: Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010; 69: 1649-54.
46. GONZALEZ A, ICEN M, KREMERS HM et al.: Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008; 35: 1009-14.
47. GONZALEZ A, MARADIT KREMERS H, CROW-SON CS et al.: The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7.
48. GOODSON N, MARKS J, LUNT M et al.: Cardiovascular admissions and mortality in an inception cohort of patients with rheuma-toid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-601.
49. BOKI KA, DROSOS AA, TZIOUFAS AG et al.: Examination of HLA-DR4 as a severity marker for rheumatoid arthritis in Greek patients. Ann Rheum Dis 1993; 52: 517-9.
50. BALSA A, MINAUR NJ, PASCUAL-SALCEDO D et al.: Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain). Rheumatology (Oxford) 2000; 39: 844-9.
51. BENAZET JF, REVIRON D, MERCIER P et al.: HLA-DRB1 alleles associated with rheumatoid arthritis in southern France. Absence of extraarticular disease despite expression of the shared epitope. J Rheumatol 1995; 22: 607-10.
52. RONDA E, RUIZ MT, PASCUAL E et al.: Differences between Spanish and British patients in the severity of rheumatoid arthritis: comment on the article by Drosos et al. Arthritis Rheum 1994; 37: 147-8.
53. DROSOS AA, LANCHBURY JS, PANAYI GS et al.: Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum 1992; 35: 745-8.
54. DESSEIN PH, NORTON GR, JOFFE BI et al.: Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid arthritis: a cross-sectional study. Clin Exp Rheumatol 2013; 31: 53-61.